[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anne M. Connolly\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100470940",false,"NCT05412394","Once Weekly Infant Corticosteroid Trial for DMD","Phase-2 Trial of 5mg\u002Fkg\u002FWeek Prednisolone in Young Boys With DMD","Inclusion Criteria:\n\n* Subjects ages 1 month through 30 months\n* Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.\n\nExclusion Criteria:\n\n* Prior treatment with Glucocorticosteroids","MALE","1 Month","30 Months",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg\u002Fkg\u002Fweek) will be equally effective to the 10mg\u002Fkg\u002Fweek dose.",[26],"Duchenne Muscular Dystrophy",[26,28,29,30],"DMD","Steroid","Muscular Dystrophy","RECRUITING","2025-08-08",{"date":34,"type":35},"2025-08-13","ACTUAL",{"date":37,"type":35},"2021-04-30",{"date":39,"type":20},"2026-12",{"name":41,"class":42},"Anne M. Connolly","OTHER",4,""]